Sequentscientific · risk themes across the available quarters.
Bear-case history
Analyst questioned management on Trump-era pharma tariffs and Biocaut Act; Dr. Hari acknowledged ~17-18% US exposure but expressed more opportunity than risk given strong regulatory audit track record (5 audits in 12-15 months, all VAI/no 483).
Sequential gross margin declined QoQ despite YoY improvement due to less favorable product mix in API. Management acknowledged some quarters may see swings between 48-49% before sustaining upward trajectory.
Management declined to break out companion animal financials despite direct analyst question, citing ~5% of total business. This limits visibility into higher-margin segment performance and growth trajectory.
CDMO business buildout has 12-18 month timeline with team building still in progress. Management specifically said 'I don't want to just come up CDM just few things' indicating early-stage nature of this growth lever.
Sequent API business is tracking below Rs 100 crore run rate target. Management expects recovery from Q4 onwards but timing remains dependent on innovator customer scheduling decisions.
Management claims no current tariff impact as US represents only 35% of Vash's formulation business with US-based manufacturing. However, broader geopolitical escalation or API sourcing disruptions could indirectly affect the business.
Q2 margins benefited from initial CDMO service income and validation contracts. While management insists these are not one-offs, the sustainability of this revenue stream depends on continued contract wins and new product validations.
ESOP charges of Rs 23 crore in H1 FY26 will continue as recurring P&L item for next 2-3 years, with a new scheme being finalized for Vash post-merger. This will partially offset operating profit improvements.